Jessica Tassan
Stock Analyst at Piper Sandler
(0.53)
# 4,288
Out of 4,988 analysts
230
Total ratings
41.6%
Success rate
-3.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OSCR Oscar Health | Reiterated: Buy | $36 → $48 | $32.13 | +49.39% | 10 | Sep 17, 2026 | |
| CI The Cigna Group | Reiterated: Buy | $370 → $346 | $275.28 | +25.69% | 7 | Aug 26, 2026 | |
| CVS CVS Health | Reiterated: Buy | $99 → $113 | $88.84 | +27.19% | 12 | Aug 26, 2026 | |
| CTEV Claritev | Rated: Buy | $61 → $73 | $30.81 | +136.94% | 11 | Aug 18, 2026 | |
| DOCS Doximity | Reiterated: Buy | $42 → $47 | $26.11 | +80.01% | 14 | Aug 7, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $36 | $19.85 | +81.36% | 12 | Aug 7, 2026 | |
| OMCL Omnicell | Reiterated: Buy | $49 → $45 | $32.23 | +39.62% | 22 | Aug 3, 2026 | |
| HUM Humana | Upgraded: Buy | $254 → $463 | $386.22 | +19.88% | 8 | Jul 30, 2026 | |
| UNH UnitedHealth Group | Reiterated: Buy | $420 → $475 | $376.90 | +26.03% | 20 | Jul 15, 2026 | |
| PHR Phreesia | Downgraded: Hold | $34 → $12 | $10.04 | +19.52% | 16 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 → $2 | $1.79 | +11.73% | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 → $95 | $94.90 | +0.11% | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $8.35 | +259.28% | 14 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $9 | $6.30 | +42.86% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.69 | n/a | 22 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $8 | $13.75 | n/a | 13 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $13 → $10 | $4.70 | n/a | 4 | Jan 17, 2024 |
Oscar Health
Sep 17, 2026
Reiterated: Buy
Price Target: $36 → $48
Current: $32.13
Upside: +49.39%
The Cigna Group
Aug 26, 2026
Reiterated: Buy
Price Target: $370 → $346
Current: $275.28
Upside: +25.69%
CVS Health
Aug 26, 2026
Reiterated: Buy
Price Target: $99 → $113
Current: $88.84
Upside: +27.19%
Claritev
Aug 18, 2026
Rated: Buy
Price Target: $61 → $73
Current: $30.81
Upside: +136.94%
Doximity
Aug 7, 2026
Reiterated: Buy
Price Target: $42 → $47
Current: $26.11
Upside: +80.01%
Privia Health Group
Aug 7, 2026
Reiterated: Buy
Price Target: $36
Current: $19.85
Upside: +81.36%
Omnicell
Aug 3, 2026
Reiterated: Buy
Price Target: $49 → $45
Current: $32.23
Upside: +39.62%
Humana
Jul 30, 2026
Upgraded: Buy
Price Target: $254 → $463
Current: $386.22
Upside: +19.88%
UnitedHealth Group
Jul 15, 2026
Reiterated: Buy
Price Target: $420 → $475
Current: $376.90
Upside: +26.03%
Phreesia
May 28, 2026
Downgraded: Hold
Price Target: $34 → $12
Current: $10.04
Upside: +19.52%
May 12, 2026
Reiterated: Hold
Price Target: $4 → $2
Current: $1.79
Upside: +11.73%
May 6, 2026
Reiterated: Buy
Price Target: $60 → $95
Current: $94.90
Upside: +0.11%
Mar 2, 2026
Reiterated: Buy
Price Target: $30
Current: $8.35
Upside: +259.28%
Feb 26, 2026
Reiterated: Buy
Price Target: $12 → $9
Current: $6.30
Upside: +42.86%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $3.69
Upside: n/a
May 23, 2025
Reiterated: Hold
Price Target: $10 → $8
Current: $13.75
Upside: n/a
Jan 17, 2024
Reiterated: Hold
Price Target: $13 → $10
Current: $4.70
Upside: n/a